GlassScriptPhysician profile
Sadik Yesil
NPI 1760471817
$5,596.47
in general payments reported to CMS, 2019-2025
37 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $262 · 2021: $174 · 2022: $397 · 2023: $785 · 2024: $1,896 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,150.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,000.89 | 2021-2025 | |
| Abbvie INC. | $477.46 | 2021-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $468.77 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $327.25 | 2019-2025 | |
| Lilly USA, LLC | $321.00 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Sunovion Pharmaceuticals INC. | $310.48 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $228.82 | 2019-2024 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $209.74 | 2020-2025 | Rytary, Crexont |
| Otsuka America Pharmaceutical, INC. | $192.58 | 2023-2025 | Rexulti |
| Emd Serono, INC. | $190.81 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $176.84 | 2023-2025 | Rexulti, Vyepti |
| Argenx US, INC. | $173.26 | 2023-2025 | Vyvgart |
| Supernus Pharmaceuticals, INC. | $151.21 | 2019-2021 | |
| Biogen, INC. | $124.16 | 2023-2025 | Vumerity, Plegridy, Avonex |
| Sk Life Science, INC. | $122.21 | 2020-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadik Yesil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.